Objective To compare efficacy and safety of paliperidone sustained release tablets and domestic olanzapine in treatment of schizophrenia. Methods 62 patients with schizophrenia who met the diagnostic criteria of CCMD-3 were randomly divided into 2 groups:treatment group(treated with paliperidone sustained release tablets) and control group(treated with domestic olanzapine). 12-week followe-up observation was performed. Positive and negative syndrome scale (PANSS) and treatment emergent symptom scale(TESS) were adopted to assess their clinical efficacy and adverse reaction. Results Comparison of PANSS score at each time point after l week treatment with that before treatment in the treatment group, the difference was statistically significant (P＜0. 05). Comparison of PANSS score at each time point after 2 weeks treatment with that before treatment in the control group,the difference was also statistically significant(P＜0.05). The effective rate of treatment was 90. 6 ％ in the control group while that was 93.3 ％ in the treatment group, with no statistically significant difference between the two groups(P＞0.05). The incidence rate of somnolence in the treatment group was lower than that in control group. Conclusion Paliperidone sustained release tablets can quickly and effectively control the symptoms of schizophrenia with less adverse reaction of somnolence.%目的 比较帕利哌酮缓释片与国产奥氮平治疗精神分裂症的疗效与安全性.方法 将符合CCMD-3的精神分裂症患者62例随机分为两组:治疗组(给予帕利哌酮缓释片)与对照组(给予国产奥氮平),随访观察12周.采用阳性和阴性症状量表(PANSS)及治疗不良反应量表(TESS)评价临床疗效与不良反应.结果 治疗组在治疗1周后各时间点的PANSS分值与治疗前PANSS分值比较差异有统计学意义(P＜0.05);对照组在治疗2周后各时间点的PANSS分值与治疗前PANSS分值比较差异也有统计学意义(P＜0.05).治疗组有效率为93.3%,对照组有效率为90.6%,组间疗效比较差异无统计学意义(P＞0.05).治疗组患者的嗜睡发生率比对照组低(P＜0.05).结论 帕利哌酮缓释片可快速、有效地控制精神分裂症患者的症状,较少出现嗜睡不良反应.
展开▼
